All News

The open label trial was available to patients 18 years of age and older with relapsed or refractory DLBCL after 2 or more lines of treatment.

Bezlotoxumab is administered to prevent Clostridium difficile infection from recurring in patients who are receiving treatment for the infection and are at risk for recurrence.

A pooled analysis of a 48-week open-label extension of a pair of phase 3 studies found that 99% of patients with HIV who initiated treatment using bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets maintained an undetectable viral load through 4 years of follow-up.

AQP-modulating agent discovery has proved challenging, but many powerful AQP3 permeating molecules have been identified.

Individuals with attention-deficit hyperactivity disorder and other diagnoses who are taking stimulant medications are also more likely to switch to non-stimulant medications.

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in OS for patients whose tumors expressed PD-L1 with a combined positive score ≥10 compared to chemotherapy alone, according to the study.

These services include vaccinations, routine screenings, and physical exams.

Older drugs such as lovastatin (Mevacor, Altoprev), simvastatin (Zocor), and atorvastatin (Lipitor) have the most drug interactions.

Investigators hypothesize that concurrent symptoms of anxiety and depression may be linked to concerns about adverse events.

Officials with the CDC updated their COVID-19 guidelines today, urging that vaccinated individuals in areas of substantial and high transmission wear masks in public indoor spaces, including schools, in order to prevent the spread of the Delta variant.

Many pharmacists must find a way to vaccinate hundreds of patients in an organized way, while still having to run an understaffed pharmacy.

John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discussed his history prior to joining NPC.

The clinical trial expansion is part of efforts to detect potential adverse effects in children, such as heart inflammation problems.

According to the investigators, this discrepancy remains even if the individual reported symptoms of heart failure during a routine outpatient health care appointment within the past 6 months.

Theresa McArdle, MBA, senior brand marketing manager at Pharmavite, to discuss new survey data that showed a decline in self-care among pharmacists coming out of the COVID-19 pandemic.

Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, discussed the pandemic's impact on the legislative push to grant pharmacists provider status for Medicare Part B.

The combination of pembrolizumab and chemotherapy marks the first immunotherapy regimen approved for patients with high-risk early-stage triple-negative breast cancer.

Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss the updates in the prevention and treatment of cytokine release syndrome and neurologic toxicities for patients with multiple myeloma.

Evkeeza has been approved as an adjunct to other low-density lipoprotein cholesterol-lowering therapies to treat patients 12 years and older with homozygous familial hypercholesterolemia.

According to the investigators, treatment with ruxolitinib resulted in a significant improvement in ORR after 24 weeks, with an ORR of 49.7% in the ruxolitinib arm compared to 25.6% in the best available therapy arm.

Two of the studies also found that patients with COVID-19 who received remdesivir had a significantly increased chance of discharge from the hospital by day 28.

The drug also resulted in zero cases of virologic failure and no development of resistance in virologically suppressed adults with HIV-1 who have not previously experienced virologic failure.

One dose of AstraZeneca’s COVID-19 vaccine (Vaxzevria) was 82% effective against hospitalization or death caused by either the Beta or Gamma variants of the SARS-CoV-2 virus, according to data from the Canadian Immunization Research Network, currently published as a pre-print.

The research team noted that although HCL has a good prognosis for the majority of patients, a small population will develop variants of the disease do not respond well to existing FDA-approved therapies or cannot tolerate the adverse effects of established therapies.

Heart failure outcomes improve with optimal iron levels.

APhA offers intensive certificate course on integrating education and management into practice.

Zoster vaccine recombinant, adjuvanted has been approved by the FDA for the prevention of herpes zoster in adults 18 years of age and older who are, or will be, at an increased risk of shingles because of immunodeficiency or immunosuppression.

Joint statement released supporting belief that COVID-19 vaccines are the logical fulfillment of the ethical obligation of all health care workers to put their patients first.

According to a press release from Saniona, Tesomet is the first and only investigational treatment for HO to receive orphan drug designation.

How would you respond to these patients' questions?